MicroPort CardioFlow Medtech Corporation

SEHK:2160 Voorraadrapport

Marktkapitalisatie: HK$1.7b

MicroPort CardioFlow Medtech Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jeffrey R Lindstrom

Algemeen directeur

CN¥4.0m

Totale compensatie

Percentage CEO-salaris59.8%
Dienstverband CEO1.3yrs
Eigendom CEOn/a
Management gemiddelde ambtstermijn4.1yrs
Gemiddelde ambtstermijn bestuur3.8yrs

Recente managementupdates

Recent updates

MicroPort CardioFlow Medtech Corporation (HKG:2160) Stocks Shoot Up 34% But Its P/S Still Looks Reasonable

Sep 27
MicroPort CardioFlow Medtech Corporation (HKG:2160) Stocks Shoot Up 34% But Its P/S Still Looks Reasonable

After Leaping 34% MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares Are Not Flying Under The Radar

Sep 27
After Leaping 34% MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares Are Not Flying Under The Radar

Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 43%?

Aug 07
Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 43%?

Some MicroPort CardioFlow Medtech Corporation (HKG:2160) Shareholders Look For Exit As Shares Take 26% Pounding

Jun 19
Some MicroPort CardioFlow Medtech Corporation (HKG:2160) Shareholders Look For Exit As Shares Take 26% Pounding

MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans

May 29
MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans

MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely

Apr 05
MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely

We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

Feb 23
We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 37% Undervalued

Jan 18
An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 37% Undervalued

Companies Like MicroPort CardioFlow Medtech (HKG:2160) Are In A Position To Invest In Growth

Oct 04
Companies Like MicroPort CardioFlow Medtech (HKG:2160) Are In A Position To Invest In Growth

Not Many Are Piling Into MicroPort CardioFlow Medtech Corporation (HKG:2160) Stock Yet As It Plummets 27%

May 31
Not Many Are Piling Into MicroPort CardioFlow Medtech Corporation (HKG:2160) Stock Yet As It Plummets 27%

We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

May 23
We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

The MicroPort CardioFlow Medtech Corporation (HKG:2160) Analysts Have Been Trimming Their Sales Forecasts

Apr 06
The MicroPort CardioFlow Medtech Corporation (HKG:2160) Analysts Have Been Trimming Their Sales Forecasts

MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans

Feb 08
MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans

We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

Oct 18
We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

We're Not Very Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn Rate

Jun 30
We're Not Very Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn Rate

Analysts Just Made A Major Revision To Their MicroPort CardioFlow Medtech Corporation (HKG:2160) Revenue Forecasts

Apr 04
Analysts Just Made A Major Revision To Their MicroPort CardioFlow Medtech Corporation (HKG:2160) Revenue Forecasts

MicroPort CardioFlow Medtech Corporation (HKG:2160) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Apr 03
MicroPort CardioFlow Medtech Corporation (HKG:2160) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 49% Undervalued

Jan 21
An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 49% Undervalued

Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 24%?

Sep 05
Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 24%?

We're Not Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn

Jun 07
We're Not Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn

Market Sentiment Around Loss-Making MicroPort CardioFlow Medtech Corporation (HKG:2160)

May 03
Market Sentiment Around Loss-Making MicroPort CardioFlow Medtech Corporation (HKG:2160)

Analyse CEO-vergoeding

Hoe is Jeffrey R Lindstrom's beloning veranderd ten opzichte van MicroPort CardioFlow Medtech's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-CN¥349m

Mar 31 2024n/an/a

-CN¥410m

Dec 31 2023CN¥4mCN¥2m

-CN¥472m

Compensatie versus markt: De totale vergoeding ($USD 552.49K ) Jeffrey R } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 336.37K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Jeffrey R te vergelijken met de prestaties van het bedrijf.


CEO

Jeffrey R Lindstrom (57 yo)

1.3yrs

Tenure

CN¥4,004,000

Compensatie

Mr. Jeffrey R Lindstrom is President, Executive Director & General Manager of MicroPort CardioFlow Medtech Corporation from August 29, 2023. He served as senior director of engineering in Edwards Lifescien...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Jeffrey R Lindstrom
President1.3yrsCN¥4.00mgeen gegevens
Liang Zhao
Executive Director & First VP of Total Solutions2.5yrsCN¥3.91m0.058%
HK$ 973.0k
Luying Yan
VP & Executive Director4.2yrsCN¥2.70m0.042%
HK$ 698.5k
Xiangmei Li
Joint Company Secretary4.1yrsgeen gegevensgeen gegevens
Lok Yee Chan
Joint Company Secretary4.1yrsgeen gegevensgeen gegevens

4.1yrs

Gemiddelde duur

43yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 2160 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Jeffrey R Lindstrom
President1.3yrsCN¥4.00mgeen gegevens
Liang Zhao
Executive Director & First VP of Total Solutions2.5yrsCN¥3.91m0.058%
HK$ 973.0k
Luying Yan
VP & Executive Director4.2yrsCN¥2.70m0.042%
HK$ 698.5k
Jonathan H. Chou
Independent Non-Executive Director3.8yrsCN¥254.00kgeen gegevens
Xia Wu
Non-Executive Director5.3yrsgeen gegevensgeen gegevens
Guoming Chen
Non-Executive Chairman of the Board4.2yrsCN¥3.16m0.031%
HK$ 512.6k
Junjie Zhang
Non-Executive Director5.3yrsgeen gegevensgeen gegevens
Zhixiang Sun
Independent Non-Executive Director3.8yrsCN¥254.00kgeen gegevens
Jiandong Ding
Independent Non-Executive Director3.3yrsCN¥254.00k0.0012%
HK$ 20.6k

3.8yrs

Gemiddelde duur

47yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 2160 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).